Table 2.
Sample | Days post XMRV Infection | Antibody Titers by ARCHITECT CMIAs | ||||
---|---|---|---|---|---|---|
1st Infection |
2nd Infection |
Immuni- zation |
Anti-gp70 | Anti-p15E | Anti-p30 | |
RIl-10 | 42 | 800 | 40 | 2 | ||
134 | 3,200 | 160 | 10 | |||
167 | 9 | 128,000 | 12,800 | 640 | ||
210 | 52 | 32,000 | 800 | 80 | ||
291 | 133 | 16 | 16,000 | 8,000 | 4,000 | |
RYh-10 | 42 | 1,600 | 80 | 10 | ||
134 | 1,600 | 80 | 10 | |||
167 | 9 | 32,000 | 6,400 | 640 | ||
210 | 52 | 8,000 | 400 | 80 | ||
291 | 133 | 16 | 4,000 | 4,000 | 2,000 | |
RLq-10 | 42 | 800 | 80 | 1 | ||
134 | 800 | 160 | 1 | |||
Anti-MuLV pAb | 16,000 | 32,000 | 64,000 | |||
Anti-Env pAb | 10,000 | |||||
Anti-His Mab | 0.039 nM | 1.18 nM | ||||
Anti-p30 Mab | 0.56 nM |
Antibody titers were determined by the three direct gp70, p15E and p30 CMIAs on samples serially diluted with negative normal human plasma, and expressed as the reciprocal of the bleed dilution giving a reactive result. For comparison, detection limits of the anti-His and anti-p30 monoclonal antibodies were also listed.